Sells branded prescription pharmaceutical products in India across gynaecology, orthopaedics, dermatology and child-care, with a 40-plus-year track record and over 20 brands ranked in the top 5 of their molecule categories. Revenue is concentrated: the top 10 brands contribute 58-60% of sales and nine of those rank top-5 in their respective categories, while five brands rank #1 in their molecules. Growth comes from medical-representative (MR) productivity rather than field-force expansion — no new MRs are planned — with the portfolio shifting toward semi-chronic and specialty therapies. In June 2026 it acquired an 85% stake in Aequitas Healthcare for Rs 20.8 crore, adding a hospital-channel business that sold to 1,000-plus hospitals and 4,000-plus specialty doctors in FY26 (Rs 53 crore revenue). The biggest cost line is employees at 24.6% of revenue, reflecting the MR-heavy sales model; raw materials are only 5.6% of revenue. Capital returns are a feature of the model — FY26 included a Rs 40 crore buyback at a 44% premium and a 200% dividend (with a 75% special dividend component). AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Branded prescription pharmaceuticals, Hospital-channel pharma supplies. Asset-light branded pharma with an MR-driven sales model, top-brand concentration, and growing hospital-channel exposure.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 226 | 237 | 209 | 269 | 287 |
| EBITDA (ex other income) | 26 | 31 | 23 | 71 | 56 |
| margin % | 11.4 | 13.0 | 11.1 | 26.3 | 19.5 |
| Owners' profit | 20 | 27 | 22 | 55 | 43 |
| EPS, as reported (₹) | 7.48 | 10.20 | 8.49 | 8.26 | 6.40 |
| ROE % · ROCE % | 15.0 · 20.6 | 16.8 · 21.0 | 12.0 · 15.5 | 23.1 · 28.1 | 15.6 · 20.3 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 6 | 40 | 35 | 55 | 47 |
| Capex | (0) | (0) | (0) | (0) | 0 |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 75 | 74 | 59 | 76 | 74 | 73 | 64 | 82 |
| Profit before tax | 15 | 39 | 9 | 14 | 17 | 15 | 12 | 18 |
| Net profit | 11 | 32 | 7 | 11 | 13 | 11 | 9 | 13 |
| EPS (₹) | 4.29 | 4.74 | 0.98 | 1.60 | 1.88 | 1.67 | 1.25 | 2.00 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 28 Aug 2026 · Newspaper publication of 47th AGM notice, Annual Report 2025-26 and e-voting | compliance | minimal | — | — |
| 27 Aug 2026 · Notice of 47th AGM and Annual Report for FY 2025-26 | board shareholder meetings | medium | — | — |
| 27 Aug 2026 · Jagsonpal Pharmaceuticals files BRSR for FY 2025-26 | compliance | low | — | — |
| 27 Aug 2026 · 47th AGM notice and FY26 annual report filed | board shareholder meetings | low | — | — |
| 27 Aug 2026 · Annual Report 2025-26 web link sent to shareholders; 47th AGM on Sept 18, 2026 | compliance | minimal | — | — |
| 24 Aug 2026 · ESOP allotment of 27,950 shares to employees under JPL ESOP 2022 | capital market events | low | — | — |
| 12 Aug 2026 · 47th AGM on Sept 18, 2026 via video conferencing; final dividend Rs. 4 per share | compliance | minimal | — | — |
| 4 Aug 2026 · Jagsonpal Pharma Q1 FY27: 9% Revenue Growth, 22% PAT Jump, Aequitas Deal Done | investor communications | medium | — | — |
| 30 Jul 2026 · Q1 FY27 Earnings Call Audio Recording Available on Company Website | investor communications | low | — | — |
| 30 Jul 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 34.3 | 28.9 | 95 of 169 | 44% |
| P/B | 5.6 | 3.3 | 124 of 163 | 24% |
| ROCE | 19.9 | 10.8 | 35 of 183 | 81% |
| ROE | 15.6 | 10.4 | 47 of 171 | 73% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 24.4 | 17.5 | 57 of 165 | 66% |
| Revenue growth | 8.8 | 16.3 | 97 of 161 | 40% |
| Profit growth | 22.2 | 30.9 | 87 of 158 | 45% |
| Market cap | 1536 | 839 | 82 of 182 | 55% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
